Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Balding's emotional impact is discussed, highlighting self-acceptance and well-being. Treatments like finasteride, minoxidil, and microneedling are mentioned, but the focus is on self-care and maintaining perspective.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The user experiences immediate hair shedding linked to stress, unlike typical telogen effluvium, and is seeking answers. A suggestion was made to use spironolactone and topical minoxidil to address potential DHT-related shedding.

The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.

Buzzing hair can improve mental health and make applying treatments like Minoxidil and microneedling easier. It helps with self-acceptance and reduces the impact of hair loss on appearance.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. The focus is on setting realistic expectations for these treatments.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

The conversation is about a person considering participating in a study for Clascoterone, a topical cream for hair loss, and seeking advice on potential side effects. They have mild hair loss and are not currently using other treatments like finasteride.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

A user experienced a loss of libido and anhedonia after severe dietary restriction while on Finasteride and Minoxidil for hair loss. They are considering reducing the Finasteride dose or taking a break to see if symptoms improve.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

Some people don't see results with FDA-approved hair loss treatments like finasteride or minoxidil due to underlying issues. The video suggests addressing these issues, especially if there are atypical symptoms or other health conditions.

Wearing a high-quality hair system for festivals is generally considered acceptable, with the main concern being potential damage if someone pulls on it. Baldness is respected in these scenes, but long hair is more fetishized, making hair systems appealing for those seeking hookups.

The conversation humorously discusses hair loss treatments, mentioning "oral miraclegro," "topical roundup," "spectracide," "Cow Dung mesotherapy," and "weekly Foot stepping sessions." The user jokingly considers switching to "weed and feed" as a treatment.

The user changed their hair loss treatment in October/November, experienced increased shedding, and now sees no new hair growth, with a worsening condition and a possible bald spot. They also have severe seborrheic dermatitis, which may be affecting their scalp and hair loss.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The user experienced significant hair shedding after pausing their hair care regimen, which included finasteride, micro-needling, Nizoral shampoo, vitamin D, essential oils, melatonin, caffeine, exercise, and protein intake. They are concerned if the shedding is due to the break in their routine or a normal phase of finasteride use.

12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

The conversation discusses the appearance of new baby hairs with treatments like castor oil, finasteride, minoxidil, and dermarolling. Users note that baby hairs often go unreported after initial excitement, with some seeing growth and others losing interest in updates.

A 30-year-old male experienced rapid hair shedding over 6-7 months due to stress, depression, and nicotine/alcohol use, but has since stopped these habits. He seeks advice on remedies, medications, or diet changes to address hair loss.